NCT07088250 Statins for Treatment of Primary Intracerebral Hemorrhage
| NCT ID | NCT07088250 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Second Hospital of Anhui Medical University |
| Condition | Cerebrovascular Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 264 participants |
| Start Date | 2023-05-06 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 264 participants in total. It began in 2023-05-06 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The STOP ICH trial is a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study designed to assess the efficacy and safety of atorvastatin in patients with intracerebral hemorrhage (ICH) presenting within 3 to 24 hours of symptom onset.
Eligibility Criteria
Inclusion Criteria: * Patients with a diagnosis of spontaneous intracerebral hemorrhage (ICH) confirmed by computed tomography (CT); * Age 18-80 years; * Hematoma located in the supratentorial region; * Time from symptom onset or last known well to baseline CT ranging from 3 to 24 hours; * Atorvastatin treatment can be initiated within 48 hours of symptom onset or last known well; * Glasgow Coma Scale (GCS) score ≥9; * Baseline hematoma volume of 5-35 mL; * Signed informed consent obtained. Exclusion Criteria: * ICH secondary to trauma, tumor, aneurysm, arteriovenous malformation (AVM), vascular anomaly, hemorrhagic transformation of infarction, cerebral venous thrombosis, or anticoagulant-related ICH; * Patients who have undergone or are scheduled for immediate surgical intervention; * Pregnancy or lactation; * Use of oral anticoagulants within 1 month prior to symptom onset; * Pre-stroke mRS \>1; * Known allergy to statins, active liver disease, liver dysfunction, or rhabdomyolysis; * Known terminal illness with a pre-stroke life expectancy of less than three months, or patients with planned withdrawal of care.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07088250 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Cerebrovascular Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07088250 currently recruiting?
Yes, NCT07088250 is actively recruiting participants. Contact the research team at qili_md@126.com for enrollment information.
Where is the NCT07088250 trial being conducted?
This trial is being conducted at Anqing, China, Fuyang, China, Fuyang, China, Fuyang, China and 11 additional locations.
Who is sponsoring the NCT07088250 clinical trial?
NCT07088250 is sponsored by The Second Hospital of Anhui Medical University. The trial plans to enroll 264 participants.